1,2-Diglycyl-glycerin | 89941-27-5

• 英文名称: 1,2-Diglycyl-glycerin
• 英文别名: [2-(2-Aminoacetyl)oxy-3-hydroxypropyl] 2-aminoacetate
• CAS: 89941-27-5
• 化学式: C₇H₁₄N₂O₅
• 分子量: 206.199
• InChiKey: VMSAJZNFRKMALZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  14
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  125
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Trimethylglycylglycerin compositions and their use in developing anti-cancer drugs and RNA vaccines
  申请人：WJWU & LYNN Institute for Stem Cell Research

  公开号：US11326164B2

  公开（公告）日：2022-05-10

  This invention generally relates to a group of novel chemical compositions and their use for formulating RNA- and/or DNA-based medicine drugs/vaccines into stable compound complexes useful for both in-vitro and in-vivo delivery. Particularly, the present invention teaches the synthesis of a group of novel trimethylglycyl chemicals and their use for formulating cosmetic, therapeutic- and/or pharmaceutical-grade nucleic acid compositions, including but not limited microRNA precursors (pre-miRNA/miRNA), small hairpin RNAs (shRNA), short interfering RNAs (siRNA), ribozymes, antisense oligonucleotides, RNA-DNA hybrids and DNA-based vectors/vaccines, with or without modification, into delivery complexes, which can then be absorbed by cells in vivo, ex vivo and/or in vitro through an active mechanism of endocytosis via acetylcoline receptors for releasing the therapeutic and pharmaceutical effects of the formulated nucleic acid compositions.

  本发明一般涉及一组新型化学组合物，及其用于将基于 RNA 和/或 DNA 的药物/疫苗配制成稳定的化合物复合物，既可用于体外给药，也可用于体内给药。特别是，本发明教导了一组新型三甲基甘氨酰化学品的合成及其用于配制化妆品级、治疗级和/或药物级核酸组合物的方法，包括但不限于 microRNA 前体（pre-miRNA/miRNA）、小发夹 RNA（shRNA）、短干扰 RNA（siRNA）、核酶、它们可以通过乙酰胆碱受体的内吞活性机制被体内、体外和/或体外细胞吸收，从而释放所配制核酸组合物的治疗和药效。
• NOVEL SUGAR ALCOHOL-BASED COMPOSITIONS FOR DELIVERING NUCLEIC ACID-BASED DRUGS IN VIVO AND IN VITRO
  申请人：Lin, Shi-Lung

  公开号：EP3086812A1

  公开（公告）日：2016-11-02
• Use of Novel Monosaccharide-like Glycylated Sugar Alcohol Compositions for Designing and Developing Anti-Diabetic Drugs
  申请人：Lin Shi-Lung

  公开号：US20150209377A1

  公开（公告）日：2015-07-30

  This invention is related to a novel sugar-like chemical composition and its use for diabetes therapy. Particularly, the present invention teaches the use of monosaccharide-like glycylated sugar alcohol compounds to block or reduce sugar absorption in diabetes patients, so as to prevent the risk of hyperglycemia symptoms. Glycylation of sugar alcohols is a totally novel reaction that has never been reported before. Therefore, the novelty of the present invention is that for the first time glycylated sugar alcohols not only was found but also was found to be useful for treating Diabetes mellitus. In addition, the present invention teaches a method for producing these glycylated sugar alcohols. In sum, the present invention includes not only a kind of novel sugar-like chemical compositions and its use for treating diabetes but also a state-of-the-art protocol and methodology for producing such a novel composition via glycylation of sugars and sugar alcohols.
• USE OF NOVEL MONOSACCHARIDE-LIKE GLYCYLATED SUGAR ALCOHOL COMPOSITIONS FOR DESIGNING AND DEVELOPING ANTI-DIABETIC DRUGS
  申请人：LIN Shi-Lung

  公开号：US20160220525A1

  公开（公告）日：2016-08-04

  This invention is related to a novel sugar-like chemical composition and its use for diabetes therapy. Particularly, the present invention teaches the use of monosaccharide-like glycylated sugar alcohol compounds to block or reduce sugar absorption in diabetes patients, so as to prevent the risk of hyperglycemia symptoms. Glycylation of sugar alcohols is a totally novel reaction that has never been reported before. Therefore, the novelty of the present invention is that for the first time glycylated sugar alcohols not only was found but also was found to be useful for treating Diabetes mellitus. In addition, the present invention teaches a method for producing these glycylated sugar alcohols. In sum, the present invention includes not only a kind of novel sugar-like chemical compositions and its use for treating diabetes but also a state-of-the-art protocol and methodology for producing such a novel composition via glycylation of sugars and sugar alcohols.
• Novel Trimethylglycylglycerin Compositions and Their Use in Developing Anti-Cancer Drugs and RNA Vaccines
  申请人：WJWU & LYNN Institute for Stem Cell Research

  公开号：US20210095280A1

  公开（公告）日：2021-04-01

  This invention generally relates to a group of novel chemical compositions and their use for formulating RNA- and/or DNA-based medicine drugs/vaccines into stable compound complexes useful for both in-vitro and in-vivo delivery. Particularly, the present invention teaches the synthesis of a group of novel trimethylglycyl chemicals and their use for formulating cosmetic, therapeutic- and/or pharmaceutical-grade nucleic acid compositions, including but not limited microRNA precursors (pre-miRNA/miRNA), small hairpin RNAs (shRNA), short interfering RNAs (siRNA), ribozymes, antisense oligonucleotides, RNA-DNA hybrids and DNA-based vectors/vaccines, with or without modification, into delivery complexes, which can then be absorbed by cells in vivo, ex vivo and/or in vitro through an active mechanism of endocytosis via acetylcoline receptors for releasing the therapeutic and pharmaceutical effects of the formulated nucleic acid compositions.